Australian-based Lumitron Co-Founder and Executive Chairman, Mr. Maurie Stang said, "The system will provide up to a thousand times improvement in image detail, far lower X-ray dose and the ability to treat simultaneously at the same cellular level, which is set to transform the landscape for both patients and practitioners. A range of immunotherapies and contrast agents enabled by the ultra-bright Lumitron laser-based x-ray is being developed here in Australia leveraging the world-class expertise Australia enjoys in life sciences. We aim to not have to remove a breast or prostate due to the unmatched capabilities of the Lumitron system.”
Dr. Barty, who was previously the CTO of the National Ignition Facility Directorate at the Lawrence Livermore National Laboratory which recently achieved nuclear fusion ignition for the first time further added, “The Lumitron laser-based x-ray technology leverages hundreds of millions of dollars of investment by the leading US research labs to bring compact, electron beam and x-ray systems into commercial reality. While initial deployment of the technology targets unmet needs in clinical and industrial imaging, Lumitron’s unique platform has applicability across an incredibly wide array of additional and impactful applications.”
Ad Statistics
Times Displayed: 21862
Times Visited: 433 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
With respect to HyperVIEW™ EBCS x-ray source development, Lumitron Technologies has been awarded multiple US Government research contracts in addition to having several active programs with major industry leaders in healthcare and non-destructive materials analysis. Further, the company has signed an agreement with one of the world's largest commercial imaging groups showing the potential for wide-scale adoption of this breakthrough technology.
Back to HCB News
